Cached score snapshot

US.LH · Labcorp

110分制 51/110;5D動能v2 8/50;排序分 59/160

Ranking score 59/160
Main score 51/110
5D momentum v2 8/50
Rank #214
Setup grade F 26.2

Score breakdown

避免

Medium twelvedata

Score and price trend

F 26.2 Low sample confidence

Main score, 5D momentum v2, close price, and improving or exit-review turn signals are plotted from archived daily snapshots.

Move the mouse over the chart lines to inspect readings.

0 40 80 110 Score 06-12 07-28 09-09 09-30 10-20 $242.14$321.23$400.32 Price Projection date
Historical projection
Model Median P25/P75 歷史相似情境上漲比例 Down5 Actual / compare
Rolling DOE best · score 2.226 · anchors 120 +1.75% -0.57% / +4.16% 66.3% 2.5% Actual -4.10% · vs median -5.85% · inside 25-75 band
30D observation +9.81% +1.19% / +15.41% 80% 6.3% Actual outcome pending · 1 / 30 bars observed
Historical projection 10D n=160 +1.40% -0.96% / +3.83% 63.1% 3.8% Actual outcome pending · 1 / 10 bars observed

歷史情境統計基於已存檔相似 setup;圖中投影中位線為統計中位數的線性插值展示,並非價格路徑預測或買賣建議。

2026-06-12 → 2026-10-20 · 119 archived points · 3 Improving turn signal · 6 Deteriorating signal

Summary

score_with_momentum_v2 = main score + 5D momentum v2

Ranking score 59
Display grade 避免
Model version cursor_18_27_news_v2_160
Main score 51/110 (避免)
5D momentum v2 8/50 (弱)
Score with momentum v2 59/160 (低排序)
Risk level Medium

Audit trace

Full calculation detail

Calculation detail · 8 sections

Market inputs

Bar count 60
ma20 329.565
ma50 307.5992
close 324.86
prevClose 326.89
avgVolume20 585844
volumeRatio 1.04
changePercent -0.62

Metrics snapshot

close 324.86
volume 610675
changePercent -0.62

110-point main rating

基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10

Main score 51/110
Main rating 避免
5D momentum v2 8/50
Score with momentum v2 59/160
Formula score_with_momentum_v2 = main_score + momentum_5d_v2_score

基本面 — 3.3/5 · 一般

Dimension score 3.3/5
Dimension grade 一般

Sub-items

pbPoints 0.4
pePoints 0.2
epsPoints 0.6
roePoints 0.4
debtPoints 0.4
marginPoints 0
turnoverUsdM 198.3839
volumePoints 0.5
revenuePoints 0
dividendPoints 0.3
marketCapPoints 0.5

資金流 — 7.6/20 · 較差

Dimension score 7.6/20
Dimension grade 較差

Sub-items

cmfPoints 1.6
mfiPoints 2.4
obvPoints 0.8
vwapPoints 0.8

institutional

score 2

details

source optional-neutral

warning

code INSTITUTIONAL_DATA_OPTIONAL
symbol US.LH
message Institutional ownership is unavailable; neutral 2/4 money-flow treatment used.
optional true
holderCount n/a
holderPoints 2
top10ShareRatio n/a
concentrationPenalty 0
institutionPoints 2

市場環境 — 9.6/15 · 一般

Dimension score 9.6/15
Dimension grade 一般

Sub-items

vix

score 2.4

details

source twelvedata+fred
vixClose 15.3

trend

score 3.4

details

qqq

ma20 717.385
ma50 711.3218
name QQQ
close 718.36
points 2

spy

ma20 768.6995
ma50 757.5966
name SPY
close 765.96
points 1.4
source twelvedata+fred
atrPct 2.2514
atrPoints 3
cciPoints 0.8
vixPoints 2.4
marketTrendPoints 3.4

催化劑 — 2/20 · 較差

Dimension score 2/20
Dimension grade 較差

Sub-items

catalyst

score 2

details

source finnhub_news_keyword_model
articleCount 4
catalystCount 0
catalystPoints 2

風險管理 — 7.2/10 · 良好

Dimension score 7.2/10
Dimension grade 良好

Sub-items

position

score 1.4

details

atrPct 2.2514
turnoverUsdM 198.3839
liquidityPoints 0.4
volatilityPoints 1
rrPoints 1.4

stopLevels

symbol US.LH
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 310.2322

strength_details

ma_score 1.5
atr_score 2
rsi_score 2
macd_score 1.5
volume_score 2
market_adjustment 1
risk_reward_ratio 1.1
stop_loss_percent 4.5
take_profit_price 341.3041
target_multiplier 1.9
technical_strength 1.78
take_profit_percent 5.1
positionPoints 1.4
stopLossPoints 2.4

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.2
stopLossPercent 4.5028
diversificationPoints 2

技術信號 — 17.3/30 · 較差

Dimension score 17.3/30
Dimension grade 較差

Sub-items

bbPoints 2.4
adxPoints 3
sarPoints 1.2
vcpPoints 2.2
macdPoints 2.4

vcpPayload

vcp_pass false
vcp_score 2.2
vcp_reason 波幅收縮(14.6%→4.8%);跌縮量(近10日4日);站上MA50;Ready=Y;Confirm=N

vcp_metrics

up_days 2
vol_ref 665553.3333
down_days 7
vcp_ready true
above_ma50 true
avg_vol_10 602070
avg_vol_20 582235
avg_vol_30 665553.3333
range_pct_10 0.0481
range_pct_20 0.0815
range_pct_30 0.1461
up_expand_ok false
lookback_used 59
near_20d_high true
contraction_ok true
down_shrink_ok true
up_expand_days 1
breakout_20d_ok false
vol_ratio_10_30 0.9046
dist_to_20d_high 0.0496
down_shrink_days 4
breakout_level_20d 341.8
vcp_breakout_confirm false
contraction_ratio_10_30 0.3295
vcp_name_en Volatility Contraction Pattern
vcp_name_zh 波動收縮形態
vol_contraction true
kdjAdxPoints 0.5
rsiKdjPoints 2.4
volumeWeight 2
maCrossPoints 1.6
shortRsiPoints 0
shortMacdPoints 0.4
volConfirmPoints 0
volumePointsTechnical 1.2

情緒分析 — 4/10 · 較差

Dimension score 4/10
Dimension grade 較差

Sub-items

sentiment

score 4

details

source finnhub_news_keyword_model
articleCount 4
negativeHits 0
positiveHits 1
sentimentScoreRaw 0.6

sentimentData

raw {"id":141364799,"url":"https://finnhub.io/api/news?id=31373309b32b11664a69313cdfde6a304286bcf2a7d2f7f46816cf13cc737438","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"LH","summary":"Labcorp Holdings (NYSE: LH) introduced the Elecsys pTau-217 blood test, the first FDA-cleared single biomarker test for Alzheimer’s disease, expanding access through primary and specialty care. The Elecsys pTau-217 test is positioned to support clinical assessment of cognitive decline with a minimally invasive blood draw instead of more invasive procedures. Labcorp announced a long-term alliance with the National Association of Community Health Centers to support clinical leadership and...","category":"company","datetime":1787887077,"headline":"Labcorp Holdings (LH) Unveiled The First FDA Cleared Single Biomarker Alzheimer’s Blood Test"}, {"id":141328528,"url":"https://finnhub.io/api/news?id=41d4184e9828e30deff21e42d2056e1128eedab4a275a35a6c0cb91c26459fec","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"LH","summary":"Over the past six months, Labcorp has been a great trade, beating the S&P 500 by 9.5%. Its stock price has climbed to $339.34, representing a healthy 20% increase. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.","category":"company","datetime":1787671604,"headline":"3 Reasons LH is Risky and 1 Stock to Buy Instead"}, {"id":141195498,"url":"https://finnhub.io/api/news?id=52a9e9c710389d8e328c113ec8d19bb6fe8cdf20776be938d5fee35bc4b11809","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"LH","summary":"Labcorp Holdings (LH) is in focus after a series of oncology diagnostics approvals and launches, including the PGDx elio tissue complete CDx for advanced melanoma and nationwide access to Roche's VENTANA PTEN RxDx Assay for prostate cancer. See our latest analysis for Labcorp Holdings. Labcorp Holdings has attracted more attention in recent months, with oncology diagnostics approvals and stronger earnings updates sitting alongside a 30 day share price return of 16.48% and a 1 year total...","category":"company","datetime":1786554523,"headline":"Is Labcorp Holdings (LH) Fully Priced Following Oncology Approvals And Raised Outlook?"}, {"id":141195499,"url":"https://finnhub.io/api/news?id=113fd9a31a9520a3488b53c1dc4d4d6b3879247f5450043b998c69734cadd53d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"LH","summary":"In late July and early August 2026, Labcorp reported higher second-quarter and year-to-date earnings, raised its 2026 revenue growth guidance, completed a large share repurchase program, and expanded its precision oncology offering by making Roche's FDA-approved VENTANA PTEN (SP218) RxDx Assay available nationwide to help guide prostate cancer treatment decisions. Together with the recent FDA approval of its PGDx elio tissue complete CDx for advanced melanoma, these developments reinforce...","category":"company","datetime":1786513280,"headline":"Did Stronger Guidance, Buybacks and New Oncology Tests Just Shift Labcorp Holdings' (LH) Investment Narrative?"}
raw_source {"id":141951219,"url":"https://finnhub.io/api/news?id=26cd988cd102699bc607d760f6bd9b391d131e19d5c76e1150c84f7afc4ce878","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"LH","summary":"Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the acquisition of MLM Medical Labs (MLM), a leading global central and specialty laboratory provider with operations across the United States, Germany and South Africa. Financial terms of the transaction were not disclosed.","category":"company","datetime":1788872700,"headline":"Labcorp Acquires MLM Medical Labs, Expanding Global Central Laboratory and Biomarker Capabilities for Clinical Trials"}, {"id":141951936,"url":"https://finnhub.io/api/news?id=b21a621d16f71d83b49537b7302fb8eba6895c3fb7b46bafa5f8a26440785630","image":"","source":"Benzinga","related":"LH","summary":"Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the acquisition of MLM Medical Labs (MLM), a leading global central and specialty laboratory provider with","category":"company","datetime":1788858623,"headline":"Labcorp Acquires MLM Medical Labs; Financial Terms Not Disclosed"}, {"id":141362285,"url":"https://finnhub.io/api/news?id=7cc64918f3b60782ab2fbcbefa34e6aa0b5f06d064dc3153c595d7e299f4f42e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"LH","summary":"Its deepest fall inside a market shock is not its deepest fall, and that gap is what a holder should size for.","category":"company","datetime":1788208182,"headline":"Market Shocks Are Not Where Hims & Hers Health Stock Has Fallen Furthest"}, {"id":141364803,"url":"https://finnhub.io/api/news?id=81fd2d01385ccdaa2f54d388659f34035e4017a6ddcf58f461004c4142cd376d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"LH","summary":"Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory solutions, today announced enhancements to the digital experience of Labcorp Global Trial Connect™, the company's portfolio of clinical trial services, data and technology that enhances and accelerates delivery. The newly redesigned platform introduces new capabilities across the Labcorp Sponsor™ and Labcorp Investigator™ portal experiences of Global Trial Connect, providing greater visibility across studies, simplify","category":"company","datetime":1788177600,"headline":"Labcorp Launches Next Generation of Labcorp Global Trial Connect™ to Help Sponsors and Investigator Sites Navigate Clinical Trial Complexity"}, {"id":141364798,"url":"https://finnhub.io/api/news?id=22001312f7ec803e2ef7a0cae3411b2f7deaa54910259b1aa3250d27030abf9f","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"LH","summary":"Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that members of the executive management team will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, Sept. 15, at 11:30 a.m. ET.","category":"company","datetime":1787923800,"headline":"Labcorp to Speak at the Morgan Stanley 24th Annual Global Healthcare Conference"}, {"id":141364799,"url":"https://finnhub.io/api/news?id=31373309b32b11664a69313cdfde6a304286bcf2a7d2f7f46816cf13cc737438","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"LH","summary":"Labcorp Holdings (NYSE: LH) introduced the Elecsys pTau-217 blood test, the first FDA-cleared single biomarker test for Alzheimer’s disease, expanding access through primary and specialty care. The Elecsys pTau-217 test is positioned to support clinical assessment of cognitive decline with a minimally invasive blood draw instead of more invasive procedures. Labcorp announced a long-term alliance with the National Association of Community Health Centers to support clinical leadership and...","category":"company","datetime":1787887077,"headline":"Labcorp Holdings (LH) Unveiled The First FDA Cleared Single Biomarker Alzheimer’s Blood Test"}, {"id":141328527,"url":"https://finnhub.io/api/news?id=2c6fa2557dbaec4227f8dbd5021b3fcd3bd488b0437bacab7dbbf50e03b31ffb","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"LH","summary":"Do Wall Street analysts favor Labcorp’s stock, given its solid performance?","category":"company","datetime":1787755302,"headline":"Are Wall Street Analysts Bullish on Labcorp Holdings Stock?"}, {"id":141328528,"url":"https://finnhub.io/api/news?id=41d4184e9828e30deff21e42d2056e1128eedab4a275a35a6c0cb91c26459fec","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"LH","summary":"Over the past six months, Labcorp has been a great trade, beating the S&P 500 by 9.5%. Its stock price has climbed to $339.34, representing a healthy 20% increase. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.","category":"company","datetime":1787671604,"headline":"3 Reasons LH is Risky and 1 Stock to Buy Instead"}, {"id":141328529,"url":"https://finnhub.io/api/news?id=1bc29ddfb3cac19c10a5e8e6813ba6adf0b2ec574897211762477575abdd5086","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"LH","summary":"DHR's Biotechnology segment grows as China demand, bioprocessing and improving discovery markets offset regional headwinds.","category":"company","datetime":1787666640,"headline":"Danaher Rides on Strength in Biotechnology Segment: Will It Sustain?"}, {"id":141328530,"url":"https://finnhub.io/api/news?id=987bec09fcd486813ecb7d3a7687216add4739a533d76a32cbe7bc626b57e328","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"LH","summary":"LH's specialty-testing expansion, strategic partnerships and buybacks support growth, while reimbursement and cost pressures pose risks.","category":"company","datetime":1787664000,"headline":"Should You Continue to Hold Labcorp Stock in Your Portfolio?"}, {"id":141313625,"url":"https://finnhub.io/api/news?id=bf0775da347333c805e2171fe144b86c4c7a909f48cddbae25b312b5df9f684d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"LH","summary":"Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it will offer the Elecsys® pTau-217 test following clearance by the U.S. Food and Drug Administration (FDA). Developed by Roche Diagnostics, the blood test aids in identifying amyloid pathology associated with Alzheimer's disease in individuals 55 and older with signs, symptoms or complaints of cognitive decline. Elecsys® pTau-217 is the first and only FDA-cleared single-biomarker blood test","category":"company","datetime":1787569320,"headline":"Labcorp to Offer First FDA-Cleared Blood Test to Detect Alzheimer's Disease Pathology in Both Primary and Specialty Care Settings"}, {"id":141311514,"url":"https://finnhub.io/api/news?id=ea8b7c842e72dc4a35a5969cc5038e4bcce5289bd7456967e5649d34ae7c971c","image":"","source":"Benzinga","related":"LH","summary":"Elecsys® pTau-217 is the first and only FDA-cleared single-biomarker blood test to both rule in and rule out amyloid pathology across specialty and primary care settingsMeasures phosphorylated Tau 217 (pTau-217), an","category":"company","datetime":1787555281,"headline":"Labcorp To Offer Elecsys pTau-217 Test Following Clearance By FDA"}, {"id":141275203,"url":"https://finnhub.io/api/news?id=089773ba910b7d77165aa048f75b768edf24f1414da740123cd9e15d62e665de","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"LH","summary":"The gap between its revenue multiple and its cash multiple is margin, and the company is spending it on purpose.","category":"company","datetime":1787257290,"headline":"Hims & Hers Health Stock Trades Below The Market On Revenue And Above It On Cash"}, {"id":141266861,"url":"https://finnhub.io/api/news?id=9cedcdf4c43cd7438e7b70ae9a03e3c4bf570d0f0bd5b655596aaaef72271d12","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"LH","summary":"IDEXX raises its 2026 EPS outlook as recurring diagnostics growth, wider margins and international expansion offset softer U.S. veterinary traffic.","category":"company","datetime":1787243820,"headline":"IDXX Raises 2026 EPS Outlook as Diagnostic Growth and Margins Improve"}, {"id":141283687,"url":"https://finnhub.io/api/news?id=c1083eb5d78d2494cc5298cb1e9b87db833a0270edea2b3e80d13132b8c82147","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"LH","summary":"OPKO Health's 12.4% monthly gain is backed by narrower losses and better margins, though profitability and clinical execution remain key risks.","category":"company","datetime":1787160900,"headline":"OPK Climbs 12.4% in the Past Month: Can the Stock Rally Keep Going?"}, {"id":141283677,"url":"https://finnhub.io/api/news?id=e5c485442820baef6b2efbdde6716d59d47ff872afaf6e93bbdacc8bd228238b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"LH","summary":"Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and the National Association of Community Health Centers (NACHC) today announced a strategic alliance to strengthen leadership development, support practice improvement and advance community health initiatives across the nation's Community Health Center (CHC) network. As part of the collaboration, the organizations are launching the NACHC Leadership Exchange for Chief Medical Officers, designed to support cu","category":"company","datetime":1787054400,"headline":"Labcorp and NACHC Launch Strategic Alliance to Strengthen Health Center Leadership and Advance Community Health"}, {"id":141249550,"url":"https://finnhub.io/api/news?id=e4a4007233f345246016d931e5f8bdf59aed8a125f2b5b12aef7d10c07478b65","image":"","source":"Benzinga","related":"LH","summary":"Collaboration will support leadership development, practice improvement and innovation across the nation's Community Health CentersBURLINGTON, N.C. and BETHESDA, Md., Aug. 18, 2026 /PRNewswire/ -- Labcorp (NYSE:LH),","category":"company","datetime":1787036885,"headline":"Labcorp And NACHC Announce Strategic Alliance To Support Practice Improvement And Advance Community Health Initiatives Across Community Health Center Network"}, {"id":141283671,"url":"https://finnhub.io/api/news?id=bc11bca6e6fed5f8b9cc8192451e1dd125d0d9e8ada4eb2d22092d7b3fd87f6d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"LH","summary":"Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced it will host an Investor Day on Thursday, September 10, 2026, from 9 a.m. to noon ET.","category":"company","datetime":1786971600,"headline":"Labcorp to Host Investor Day on September 10, 2026"}, {"id":141231125,"url":"https://finnhub.io/api/news?id=20166a2b2acd2263cfdbcc99fc419c59e514054bea615fc73fdbae8d84095aeb","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1445262091/image_1445262091.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"LH","summary":"Healthcare sector valuation check: equipment undervalued, providers near baseline, pharma/biotech overvalued. Learn more about IHF ETF here.","category":"company","datetime":1786867596,"headline":"IHF: Healthcare Dashboard For August"}, {"id":141206752,"url":"https://finnhub.io/api/news?id=659ee02b225f8ed4a921b6c898a8d79914a526a79eab67069f99e681ffb2582e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"LH","summary":"Bio-Techne's Q4 revenues beat estimates as Diagnostics and Spatial Biology deliver strong organic growth, while its Merck deal remains in focus.","category":"company","datetime":1786626060,"headline":"TECH Q4 Earnings Meet Estimates, Revenues Surpass, Stock Rises"}, {"id":141202443,"url":"https://finnhub.io/api/news?id=884f7cde5cf80530f3f3b7a4222766c9d5b1611dd2c9927a81ff8dbcb1403238","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"LH","summary":"Schechter maintains a $33 million stake after this pre-scheduled sale under a Rule 10b5-1 plan.","category":"company","datetime":1786570501,"headline":"Labcorp CEO Adam Schechter Sells 4,669 Shares for $1.5 Million"}, {"id":141195498,"url":"https://finnhub.io/api/news?id=52a9e9c710389d8e328c113ec8d19bb6fe8cdf20776be938d5fee35bc4b11809","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"LH","summary":"Labcorp Holdings (LH) is in focus after a series of oncology diagnostics approvals and launches, including the PGDx elio tissue complete CDx for advanced melanoma and nationwide access to Roche's VENTANA PTEN RxDx Assay for prostate cancer. See our latest analysis for Labcorp Holdings. Labcorp Holdings has attracted more attention in recent months, with oncology diagnostics approvals and stronger earnings updates sitting alongside a 30 day share price return of 16.48% and a 1 year total...","category":"company","datetime":1786554523,"headline":"Is Labcorp Holdings (LH) Fully Priced Following Oncology Approvals And Raised Outlook?"}, {"id":141195499,"url":"https://finnhub.io/api/news?id=113fd9a31a9520a3488b53c1dc4d4d6b3879247f5450043b998c69734cadd53d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"LH","summary":"In late July and early August 2026, Labcorp reported higher second-quarter and year-to-date earnings, raised its 2026 revenue growth guidance, completed a large share repurchase program, and expanded its precision oncology offering by making Roche's FDA-approved VENTANA PTEN (SP218) RxDx Assay available nationwide to help guide prostate cancer treatment decisions. Together with the recent FDA approval of its PGDx elio tissue complete CDx for advanced melanoma, these developments reinforce...","category":"company","datetime":1786513280,"headline":"Did Stronger Guidance, Buybacks and New Oncology Tests Just Shift Labcorp Holdings' (LH) Investment Narrative?"}, {"id":141202446,"url":"https://finnhub.io/api/news?id=bab940f55a7015d88f60068e2a5c3a85f4cdee542e259b301b823c86d91a00e2","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"LH","summary":"ALC's Q2 earnings and sales beat estimates as equipment and ocular health gains lift results, while the company raises its 2026 EPS outlook.","category":"company","datetime":1786454220,"headline":"Alcon's Q2 Earnings and Revenues Surpass Estimates, Stock Climbs"}, {"id":141175551,"url":"https://finnhub.io/api/news?id=335ee49202be9ffff32971915dd2c0726283f0b283c39a280888d2ccb6cbefef","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"LH","summary":"LH enters late 2026 with stronger growth, margin gains and raised guidance, but a rich valuation and cost risks support a measured view.","category":"company","datetime":1786373040,"headline":"Is Labcorp Stock a Buy as Growth Improves but Valuation Stays Rich?"}, {"id":141175552,"url":"https://finnhub.io/api/news?id=eee9f1f73ba5090380f2701c2893296c2b81648f037f5e89f4a44803cadf2233","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"LH","summary":"Insulet's Q2 results beat estimates on strong Omnipod demand and wider margins, but its 2026 revenue outlook takes a hit.","category":"company","datetime":1786368120,"headline":"PODD's Q2 Earnings Top Estimates, FY'26 Sales View Cut, Stock Down"}, {"id":141173754,"url":"https://finnhub.io/api/news?id=0f7603567957d6263f1c0c28e1b96d52b004f1603691cc3fddfe295396d66f4f","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"LH","summary":"Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced that the U.S. Food and Drug Administration (FDA) has approved Labcorp's PGDx elio® tissue complete CDx as a companion diagnostic to help identify patients with advanced melanoma with certain BRAF variants who may benefit from treatment with FDA-approved targeted therapiesi.","category":"company","datetime":1786359600,"headline":"Labcorp Announces FDA Approval of Companion Diagnostic Supporting Patients with Advanced Melanoma"}
data_source finnhub_news_keyword_model
article_count 4
negative_hits 0
positive_hits 1
recomputed_at_score true
sentiment_score_raw 0.6
source_article_count 27
discarded_article_count 23
sentimentPoints 4

Dimension contribution

Dimension Raw Max Norm % Contrib
基本面 3.3 5/110 66% 3.3
資金流 7.6 20/110 38% 7.6
市場環境 9.6 15/110 64% 9.6
催化劑 2 20/110 10% 2
風險管理 7.2 10/110 72% 7.2
技術信號 17.3 30/110 57.67% 17.3
情緒分析 4 10/110 40% 4

5D momentum v2 breakdown

Cursor_18.25 5D momentum v2 0-50

5D momentum v2 8/50
ret_5d -0.0234
max_score 50
max_total 50
raw_total 8
vcp_bonus 0
vol_ratio 1.0488
ret_points 0
vol_points 2
range_ratio 1.3985
volat_points 2
day_range_pct 0.0289
model_version cursor_18_27_news_v2_160
available_bars 30
breakout_points 0
partial_history false
pullback_points 4
breakout_vol_bonus 0
first_breakout_20d false
return_window_days 5
first_breakout_bonus 0
breakout_quality_points 0

Risk management

level Medium
reason risk management score >= 6.5/10

position

score 1.4

details

atrPct 2.2514
turnoverUsdM 198.3839
liquidityPoints 0.4
volatilityPoints 1
rrPoints 1.4

stopLevels

symbol US.LH
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 310.2322

strength_details

ma_score 1.5
atr_score 2
rsi_score 2
macd_score 1.5
volume_score 2
market_adjustment 1
risk_reward_ratio 1.1
stop_loss_percent 4.5
take_profit_price 341.3041
target_multiplier 1.9
technical_strength 1.78
take_profit_percent 5.1
positionPoints 1.4
stopLossPoints 2.4

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.2
stopLossPercent 4.5028
diversificationPoints 2

Calculation audit log

基本面分析總分: 3.3/5分
資金流分析總分: 7.6/20分
市場環境分析總分: 9.6/15分
催化劑分析: 2/20分
風險管理總分: 7.2/10分
技術信號分析總分: 17.3/30分
情緒分析: 4/10分
共振率(僅顯示不加分): 0%

Technical indicators

adx
value 64.29
atr
atr 7.3139
rule ATR / current price; lower volatility scores higher
score 6
atr_pct 2.25
cci
rule Cursor_18.24 CCI bands
level 超買或超賣風險
score 2
value -70.38
cmf
rule Cursor_18.24 CMF bands
level 平衡
score 4
value 0.0096
kdj
d 39.21
j 4.61
k 27.68
rule Cursor_18.24 K/D cross
score 0
signal 死叉
mfi
rule Cursor_18.24 MFI bands
level 平衡
score 6
value 50.21
obv
rule Cursor_18.24 recent_slope vs previous_slope
score 2
trend 資金流出
value 2753325
recentSlope -283287.5
previousSlope 158640
rsi
value 53.24
sar
rule Cursor_18.24 Parabolic SAR
score 4
trend 下降
value 337.6857
position SAR喺價上
distancePct 3.95
previousTrend 下降
ma50
value 307.5992
macd
macd 6.0096
trend 中性偏多
signal 8.4948
histogram -2.4853
vwap
rule Cursor_18.24 VWAP 20D consecutive close
score 2
value 330.1014
position <VWAP
consecutiveAbove 0
volume
rule Cursor_18.24 volume ratio
level 有量
ratio 1.04
score 6
avgVolume 585844
currentVolume 610675
derived
ma20 329.565
ma50 307.5992
prevClose 326.89
avgVolume10 616508
avgVolume20 585844
changePercent -0.62
avgVolumeForScore 585844
ma_cross
ma20 329.565
ma50 307.5992
rule Cursor_18.24 MA20/MA50 cross
cross 多頭
score 4
prevMa20 329.3875
prevMa50 306.5314
spreadPct 7.14
isVolumeBreakout false
bollinger
lower 317.3381
upper 341.7919
position 中間
rsi_short
value 22.07
macd_short
macd 0
trend 中性
signal 0
histogram 0
volume_ratio
ratio 1.04

Raw calculation JSON

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.4,
      "details": {
        "atrPct": 2.2514006726405427,
        "turnoverUsdM": 198.38387439324998,
        "liquidityPoints": 0.4,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.LH",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 310.2322,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 2,
        "rsi_score": 2,
        "macd_score": 1.5,
        "volume_score": 2
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.1,
      "stop_loss_percent": 4.5,
      "take_profit_price": 341.3041,
      "target_multiplier": 1.9,
      "technical_strength": 1.78,
      "take_profit_percent": 5.1
    },
    "positionPoints": 1.4,
    "stopLossPoints": 2.4,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 4.502801345281085,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 59,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 51,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 8
  },
  "market": {
    "ma20": 329.565,
    "ma50": 307.5992,
    "close": 324.86,
    "prevClose": 326.89,
    "avgVolume20": 585844,
    "volumeRatio": 1.04,
    "changePercent": -0.62
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 8,
    "details": {
      "ret_5d": -0.023447393735345545,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 8,
      "vcp_bonus": 0,
      "vol_ratio": 1.0488462562367429,
      "ret_points": 0,
      "vol_points": 2,
      "range_ratio": 1.398487346032452,
      "volat_points": 2,
      "day_range_pct": 0.028920126482796488,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 4,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 59,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 3.3,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 66,
        "contribution": 3.3
      },
      {
        "raw": 7.6,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 38,
        "contribution": 7.6
      },
      {
        "raw": 9.6,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 64,
        "contribution": 9.6
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 7.2,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 72,
        "contribution": 7.2
      },
      {
        "raw": 17.3,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 57.67,
        "contribution": 17.3
      },
      {
        "raw": 4,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 40,
        "contribution": 4
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "避免",
    "result": 51,
    "details": [
      "基本面分析總分: 3.3/5分",
      "資金流分析總分: 7.6/20分",
      "市場環境分析總分: 9.6/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 7.2/10分",
      "技術信號分析總分: 17.3/30分",
      "情緒分析: 4/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 3.3,
      "資金流": 7.6,
      "市場環境": 9.6,
      "情緒分析": 4,
      "技術信號": 17.3,
      "風險管理": 7.2
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 4,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "一般",
        "items": {
          "pbPoints": 0.4,
          "pePoints": 0.2,
          "epsPoints": 0.6,
          "roePoints": 0.4,
          "debtPoints": 0.4,
          "marginPoints": 0,
          "turnoverUsdM": 198.38387439324998,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0.3,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 1.6,
          "mfiPoints": 2.4,
          "obvPoints": 0.8,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.LH",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "一般",
        "items": {
          "vix": {
            "score": 2.4,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 15.3
            }
          },
          "trend": {
            "score": 3.4,
            "details": {
              "qqq": {
                "ma20": 717.3850005500001,
                "ma50": 711.3217994399997,
                "name": "QQQ",
                "close": 718.35999,
                "points": 2
              },
              "spy": {
                "ma20": 768.6994929500001,
                "ma50": 757.5966012200001,
                "name": "SPY",
                "close": 765.96002,
                "points": 1.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.2514006726405427,
          "atrPoints": 3,
          "cciPoints": 0.8,
          "vixPoints": 2.4,
          "marketTrendPoints": 3.4
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 4,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 4,
              "negativeHits": 0,
              "positiveHits": 1,
              "sentimentScoreRaw": 0.6
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 141364799,
                "url": "https://finnhub.io/api/news?id=31373309b32b11664a69313cdfde6a304286bcf2a7d2f7f46816cf13cc737438",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LH",
                "summary": "Labcorp Holdings (NYSE: LH) introduced the Elecsys pTau-217 blood test, the first FDA-cleared single biomarker test for Alzheimer’s disease, expanding access through primary and specialty care. The Elecsys pTau-217 test is positioned to support clinical assessment of cognitive decline with a minimally invasive blood draw instead of more invasive procedures. Labcorp announced a long-term alliance with the National Association of Community Health Centers to support clinical leadership and...",
                "category": "company",
                "datetime": 1787887077,
                "headline": "Labcorp Holdings (LH) Unveiled The First FDA Cleared Single Biomarker Alzheimer’s Blood Test"
              },
              {
                "id": 141328528,
                "url": "https://finnhub.io/api/news?id=41d4184e9828e30deff21e42d2056e1128eedab4a275a35a6c0cb91c26459fec",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LH",
                "summary": "Over the past six months, Labcorp has been a great trade, beating the S&P 500 by 9.5%. Its stock price has climbed to $339.34, representing a healthy 20% increase. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.",
                "category": "company",
                "datetime": 1787671604,
                "headline": "3 Reasons LH is Risky and 1 Stock to Buy Instead"
              },
              {
                "id": 141195498,
                "url": "https://finnhub.io/api/news?id=52a9e9c710389d8e328c113ec8d19bb6fe8cdf20776be938d5fee35bc4b11809",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LH",
                "summary": "Labcorp Holdings (LH) is in focus after a series of oncology diagnostics approvals and launches, including the PGDx elio tissue complete CDx for advanced melanoma and nationwide access to Roche's VENTANA PTEN RxDx Assay for prostate cancer. See our latest analysis for Labcorp Holdings. Labcorp Holdings has attracted more attention in recent months, with oncology diagnostics approvals and stronger earnings updates sitting alongside a 30 day share price return of 16.48% and a 1 year total...",
                "category": "company",
                "datetime": 1786554523,
                "headline": "Is Labcorp Holdings (LH) Fully Priced Following Oncology Approvals And Raised Outlook?"
              },
              {
                "id": 141195499,
                "url": "https://finnhub.io/api/news?id=113fd9a31a9520a3488b53c1dc4d4d6b3879247f5450043b998c69734cadd53d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LH",
                "summary": "In late July and early August 2026, Labcorp reported higher second-quarter and year-to-date earnings, raised its 2026 revenue growth guidance, completed a large share repurchase program, and expanded its precision oncology offering by making Roche's FDA-approved VENTANA PTEN (SP218) RxDx Assay available nationwide to help guide prostate cancer treatment decisions. Together with the recent FDA approval of its PGDx elio tissue complete CDx for advanced melanoma, these developments reinforce...",
                "category": "company",
                "datetime": 1786513280,
                "headline": "Did Stronger Guidance, Buybacks and New Oncology Tests Just Shift Labcorp Holdings' (LH) Investment Narrative?"
              }
            ],
            "raw_source": [
              {
                "id": 141951219,
                "url": "https://finnhub.io/api/news?id=26cd988cd102699bc607d760f6bd9b391d131e19d5c76e1150c84f7afc4ce878",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LH",
                "summary": "Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the acquisition of MLM Medical Labs (MLM), a leading global central and specialty laboratory provider with operations across the United States, Germany and South Africa. Financial terms of the transaction were not disclosed.",
                "category": "company",
                "datetime": 1788872700,
                "headline": "Labcorp Acquires MLM Medical Labs, Expanding Global Central Laboratory and Biomarker Capabilities for Clinical Trials"
              },
              {
                "id": 141951936,
                "url": "https://finnhub.io/api/news?id=b21a621d16f71d83b49537b7302fb8eba6895c3fb7b46bafa5f8a26440785630",
                "image": "",
                "source": "Benzinga",
                "related": "LH",
                "summary": "Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the acquisition of MLM Medical Labs (MLM), a leading global central and specialty laboratory provider with",
                "category": "company",
                "datetime": 1788858623,
                "headline": "Labcorp Acquires MLM Medical Labs; Financial Terms Not Disclosed"
              },
              {
                "id": 141362285,
                "url": "https://finnhub.io/api/news?id=7cc64918f3b60782ab2fbcbefa34e6aa0b5f06d064dc3153c595d7e299f4f42e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LH",
                "summary": "Its deepest fall inside a market shock is not its deepest fall, and that gap is what a holder should size for.",
                "category": "company",
                "datetime": 1788208182,
                "headline": "Market Shocks Are Not Where Hims & Hers Health Stock Has Fallen Furthest"
              },
              {
                "id": 141364803,
                "url": "https://finnhub.io/api/news?id=81fd2d01385ccdaa2f54d388659f34035e4017a6ddcf58f461004c4142cd376d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LH",
                "summary": "Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory solutions, today announced enhancements to the digital experience of Labcorp Global Trial Connect™, the company's portfolio of clinical trial services, data and technology that enhances and accelerates delivery. The newly redesigned platform introduces new capabilities across the Labcorp Sponsor™ and Labcorp Investigator™ portal experiences of Global Trial Connect, providing greater visibility across studies, simplify",
                "category": "company",
                "datetime": 1788177600,
                "headline": "Labcorp Launches Next Generation of Labcorp Global Trial Connect™ to Help Sponsors and Investigator Sites Navigate Clinical Trial Complexity"
              },
              {
                "id": 141364798,
                "url": "https://finnhub.io/api/news?id=22001312f7ec803e2ef7a0cae3411b2f7deaa54910259b1aa3250d27030abf9f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LH",
                "summary": "Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that members of the executive management team will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, Sept. 15, at 11:30 a.m. ET.",
                "category": "company",
                "datetime": 1787923800,
                "headline": "Labcorp to Speak at the Morgan Stanley 24th Annual Global Healthcare Conference"
              },
              {
                "id": 141364799,
                "url": "https://finnhub.io/api/news?id=31373309b32b11664a69313cdfde6a304286bcf2a7d2f7f46816cf13cc737438",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LH",
                "summary": "Labcorp Holdings (NYSE: LH) introduced the Elecsys pTau-217 blood test, the first FDA-cleared single biomarker test for Alzheimer’s disease, expanding access through primary and specialty care. The Elecsys pTau-217 test is positioned to support clinical assessment of cognitive decline with a minimally invasive blood draw instead of more invasive procedures. Labcorp announced a long-term alliance with the National Association of Community Health Centers to support clinical leadership and...",
                "category": "company",
                "datetime": 1787887077,
                "headline": "Labcorp Holdings (LH) Unveiled The First FDA Cleared Single Biomarker Alzheimer’s Blood Test"
              },
              {
                "id": 141328527,
                "url": "https://finnhub.io/api/news?id=2c6fa2557dbaec4227f8dbd5021b3fcd3bd488b0437bacab7dbbf50e03b31ffb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LH",
                "summary": "Do Wall Street analysts favor Labcorp’s stock, given its solid performance?",
                "category": "company",
                "datetime": 1787755302,
                "headline": "Are Wall Street Analysts Bullish on Labcorp Holdings Stock?"
              },
              {
                "id": 141328528,
                "url": "https://finnhub.io/api/news?id=41d4184e9828e30deff21e42d2056e1128eedab4a275a35a6c0cb91c26459fec",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LH",
                "summary": "Over the past six months, Labcorp has been a great trade, beating the S&P 500 by 9.5%. Its stock price has climbed to $339.34, representing a healthy 20% increase. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.",
                "category": "company",
                "datetime": 1787671604,
                "headline": "3 Reasons LH is Risky and 1 Stock to Buy Instead"
              },
              {
                "id": 141328529,
                "url": "https://finnhub.io/api/news?id=1bc29ddfb3cac19c10a5e8e6813ba6adf0b2ec574897211762477575abdd5086",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LH",
                "summary": "DHR's Biotechnology segment grows as China demand, bioprocessing and improving discovery markets offset regional headwinds.",
                "category": "company",
                "datetime": 1787666640,
                "headline": "Danaher Rides on Strength in Biotechnology Segment: Will It Sustain?"
              },
              {
                "id": 141328530,
                "url": "https://finnhub.io/api/news?id=987bec09fcd486813ecb7d3a7687216add4739a533d76a32cbe7bc626b57e328",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LH",
                "summary": "LH's specialty-testing expansion, strategic partnerships and buybacks support growth, while reimbursement and cost pressures pose risks.",
                "category": "company",
                "datetime": 1787664000,
                "headline": "Should You Continue to Hold Labcorp Stock in Your Portfolio?"
              },
              {
                "id": 141313625,
                "url": "https://finnhub.io/api/news?id=bf0775da347333c805e2171fe144b86c4c7a909f48cddbae25b312b5df9f684d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LH",
                "summary": "Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it will offer the Elecsys® pTau-217 test following clearance by the U.S. Food and Drug Administration (FDA). Developed by Roche Diagnostics, the blood test aids in identifying amyloid pathology associated with Alzheimer's disease in individuals 55 and older with signs, symptoms or complaints of cognitive decline. Elecsys® pTau-217 is the first and only FDA-cleared single-biomarker blood test",
                "category": "company",
                "datetime": 1787569320,
                "headline": "Labcorp to Offer First FDA-Cleared Blood Test to Detect Alzheimer's Disease Pathology in Both Primary and Specialty Care Settings"
              },
              {
                "id": 141311514,
                "url": "https://finnhub.io/api/news?id=ea8b7c842e72dc4a35a5969cc5038e4bcce5289bd7456967e5649d34ae7c971c",
                "image": "",
                "source": "Benzinga",
                "related": "LH",
                "summary": "Elecsys® pTau-217 is the first and only FDA-cleared single-biomarker blood test to both rule in and rule out amyloid pathology across specialty and primary care settingsMeasures phosphorylated Tau 217 (pTau-217), an",
                "category": "company",
                "datetime": 1787555281,
                "headline": "Labcorp To Offer Elecsys pTau-217 Test Following Clearance By FDA"
              },
              {
                "id": 141275203,
                "url": "https://finnhub.io/api/news?id=089773ba910b7d77165aa048f75b768edf24f1414da740123cd9e15d62e665de",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LH",
                "summary": "The gap between its revenue multiple and its cash multiple is margin, and the company is spending it on purpose.",
                "category": "company",
                "datetime": 1787257290,
                "headline": "Hims & Hers Health Stock Trades Below The Market On Revenue And Above It On Cash"
              },
              {
                "id": 141266861,
                "url": "https://finnhub.io/api/news?id=9cedcdf4c43cd7438e7b70ae9a03e3c4bf570d0f0bd5b655596aaaef72271d12",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LH",
                "summary": "IDEXX raises its 2026 EPS outlook as recurring diagnostics growth, wider margins and international expansion offset softer U.S. veterinary traffic.",
                "category": "company",
                "datetime": 1787243820,
                "headline": "IDXX Raises 2026 EPS Outlook as Diagnostic Growth and Margins Improve"
              },
              {
                "id": 141283687,
                "url": "https://finnhub.io/api/news?id=c1083eb5d78d2494cc5298cb1e9b87db833a0270edea2b3e80d13132b8c82147",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LH",
                "summary": "OPKO Health's 12.4% monthly gain is backed by narrower losses and better margins, though profitability and clinical execution remain key risks.",
                "category": "company",
                "datetime": 1787160900,
                "headline": "OPK Climbs 12.4% in the Past Month: Can the Stock Rally Keep Going?"
              },
              {
                "id": 141283677,
                "url": "https://finnhub.io/api/news?id=e5c485442820baef6b2efbdde6716d59d47ff872afaf6e93bbdacc8bd228238b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LH",
                "summary": "Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and the National Association of Community Health Centers (NACHC) today announced a strategic alliance to strengthen leadership development, support practice improvement and advance community health initiatives across the nation's Community Health Center (CHC) network. As part of the collaboration, the organizations are launching the NACHC Leadership Exchange for Chief Medical Officers, designed to support cu",
                "category": "company",
                "datetime": 1787054400,
                "headline": "Labcorp and NACHC Launch Strategic Alliance to Strengthen Health Center Leadership and Advance Community Health"
              },
              {
                "id": 141249550,
                "url": "https://finnhub.io/api/news?id=e4a4007233f345246016d931e5f8bdf59aed8a125f2b5b12aef7d10c07478b65",
                "image": "",
                "source": "Benzinga",
                "related": "LH",
                "summary": "Collaboration will support leadership development, practice improvement and innovation across the nation&#39;s Community Health CentersBURLINGTON, N.C. and BETHESDA, Md., Aug. 18, 2026 /PRNewswire/ -- Labcorp (NYSE:LH),",
                "category": "company",
                "datetime": 1787036885,
                "headline": "Labcorp And NACHC Announce Strategic Alliance To Support Practice Improvement And Advance Community Health Initiatives Across Community Health Center Network"
              },
              {
                "id": 141283671,
                "url": "https://finnhub.io/api/news?id=bc11bca6e6fed5f8b9cc8192451e1dd125d0d9e8ada4eb2d22092d7b3fd87f6d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LH",
                "summary": "Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced it will host an Investor Day on Thursday, September 10, 2026, from 9 a.m. to noon ET.",
                "category": "company",
                "datetime": 1786971600,
                "headline": "Labcorp to Host Investor Day on September 10, 2026"
              },
              {
                "id": 141231125,
                "url": "https://finnhub.io/api/news?id=20166a2b2acd2263cfdbcc99fc419c59e514054bea615fc73fdbae8d84095aeb",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1445262091/image_1445262091.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LH",
                "summary": "Healthcare sector valuation check: equipment undervalued, providers near baseline, pharma/biotech overvalued. Learn more about IHF ETF here.",
                "category": "company",
                "datetime": 1786867596,
                "headline": "IHF: Healthcare Dashboard For August"
              },
              {
                "id": 141206752,
                "url": "https://finnhub.io/api/news?id=659ee02b225f8ed4a921b6c898a8d79914a526a79eab67069f99e681ffb2582e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LH",
                "summary": "Bio-Techne's Q4 revenues beat estimates as Diagnostics and Spatial Biology deliver strong organic growth, while its Merck deal remains in focus.",
                "category": "company",
                "datetime": 1786626060,
                "headline": "TECH Q4 Earnings Meet Estimates, Revenues Surpass, Stock Rises"
              },
              {
                "id": 141202443,
                "url": "https://finnhub.io/api/news?id=884f7cde5cf80530f3f3b7a4222766c9d5b1611dd2c9927a81ff8dbcb1403238",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LH",
                "summary": "Schechter maintains a $33 million stake after this pre-scheduled sale under a Rule 10b5-1 plan.",
                "category": "company",
                "datetime": 1786570501,
                "headline": "Labcorp CEO Adam Schechter Sells 4,669 Shares for $1.5 Million"
              },
              {
                "id": 141195498,
                "url": "https://finnhub.io/api/news?id=52a9e9c710389d8e328c113ec8d19bb6fe8cdf20776be938d5fee35bc4b11809",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LH",
                "summary": "Labcorp Holdings (LH) is in focus after a series of oncology diagnostics approvals and launches, including the PGDx elio tissue complete CDx for advanced melanoma and nationwide access to Roche's VENTANA PTEN RxDx Assay for prostate cancer. See our latest analysis for Labcorp Holdings. Labcorp Holdings has attracted more attention in recent months, with oncology diagnostics approvals and stronger earnings updates sitting alongside a 30 day share price return of 16.48% and a 1 year total...",
                "category": "company",
                "datetime": 1786554523,
                "headline": "Is Labcorp Holdings (LH) Fully Priced Following Oncology Approvals And Raised Outlook?"
              },
              {
                "id": 141195499,
                "url": "https://finnhub.io/api/news?id=113fd9a31a9520a3488b53c1dc4d4d6b3879247f5450043b998c69734cadd53d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LH",
                "summary": "In late July and early August 2026, Labcorp reported higher second-quarter and year-to-date earnings, raised its 2026 revenue growth guidance, completed a large share repurchase program, and expanded its precision oncology offering by making Roche's FDA-approved VENTANA PTEN (SP218) RxDx Assay available nationwide to help guide prostate cancer treatment decisions. Together with the recent FDA approval of its PGDx elio tissue complete CDx for advanced melanoma, these developments reinforce...",
                "category": "company",
                "datetime": 1786513280,
                "headline": "Did Stronger Guidance, Buybacks and New Oncology Tests Just Shift Labcorp Holdings' (LH) Investment Narrative?"
              },
              {
                "id": 141202446,
                "url": "https://finnhub.io/api/news?id=bab940f55a7015d88f60068e2a5c3a85f4cdee542e259b301b823c86d91a00e2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LH",
                "summary": "ALC's Q2 earnings and sales beat estimates as equipment and ocular health gains lift results, while the company raises its 2026 EPS outlook.",
                "category": "company",
                "datetime": 1786454220,
                "headline": "Alcon's Q2 Earnings and Revenues Surpass Estimates, Stock Climbs"
              },
              {
                "id": 141175551,
                "url": "https://finnhub.io/api/news?id=335ee49202be9ffff32971915dd2c0726283f0b283c39a280888d2ccb6cbefef",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LH",
                "summary": "LH enters late 2026 with stronger growth, margin gains and raised guidance, but a rich valuation and cost risks support a measured view.",
                "category": "company",
                "datetime": 1786373040,
                "headline": "Is Labcorp Stock a Buy as Growth Improves but Valuation Stays Rich?"
              },
              {
                "id": 141175552,
                "url": "https://finnhub.io/api/news?id=eee9f1f73ba5090380f2701c2893296c2b81648f037f5e89f4a44803cadf2233",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LH",
                "summary": "Insulet's Q2 results beat estimates on strong Omnipod demand and wider margins, but its 2026 revenue outlook takes a hit.",
                "category": "company",
                "datetime": 1786368120,
                "headline": "PODD's Q2 Earnings Top Estimates, FY'26 Sales View Cut, Stock Down"
              },
              {
                "id": 141173754,
                "url": "https://finnhub.io/api/news?id=0f7603567957d6263f1c0c28e1b96d52b004f1603691cc3fddfe295396d66f4f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LH",
                "summary": "Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced that the U.S. Food and Drug Administration (FDA) has approved Labcorp's PGDx elio® tissue complete CDx as a companion diagnostic to help identify patients with advanced melanoma with certain BRAF variants who may benefit from treatment with FDA-approved targeted therapiesi.",
                "category": "company",
                "datetime": 1786359600,
                "headline": "Labcorp Announces FDA Approval of Companion Diagnostic Supporting Patients with Advanced Melanoma"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 4,
            "negative_hits": 0,
            "positive_hits": 1,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.6,
            "source_article_count": 27,
            "discarded_article_count": 23
          },
          "sentimentPoints": 4
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 17.3,
        "grade": "較差",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 2.2,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 2.2,
            "vcp_reason": "波幅收縮(14.6%→4.8%);跌縮量(近10日4日);站上MA50;Ready=Y;Confirm=N",
            "vcp_metrics": {
              "up_days": 2,
              "vol_ref": 665553.3333333334,
              "down_days": 7,
              "vcp_ready": true,
              "above_ma50": true,
              "avg_vol_10": 602070,
              "avg_vol_20": 582235,
              "avg_vol_30": 665553.3333333334,
              "range_pct_10": 0.048143786497068956,
              "range_pct_20": 0.08148125597122616,
              "range_pct_30": 0.1460936756169943,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": true,
              "down_shrink_ok": true,
              "up_expand_days": 1,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.9046157082327486,
              "dist_to_20d_high": 0.049561148319518675,
              "down_shrink_days": 4,
              "breakout_level_20d": 341.79999,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.3295405245555246
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 1.2
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 1.4,
            "details": {
              "atrPct": 2.2514006726405427,
              "turnoverUsdM": 198.38387439324998,
              "liquidityPoints": 0.4,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.LH",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 310.2322,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 2,
              "rsi_score": 2,
              "macd_score": 1.5,
              "volume_score": 2
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.1,
            "stop_loss_percent": 4.5,
            "take_profit_price": 341.3041,
            "target_multiplier": 1.9,
            "technical_strength": 1.78,
            "take_profit_percent": 5.1
          },
          "positionPoints": 1.4,
          "stopLossPoints": 2.4,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 4.502801345281085,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 64.29,
    "atr": {
      "atr": 7.3139,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.25
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": -70.38
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "平衡",
      "score": 4,
      "value": 0.0096
    },
    "kdj": {
      "d": 39.21,
      "j": 4.61,
      "k": 27.68,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "平衡",
      "score": 6,
      "value": 50.21
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 2,
      "trend": "資金流出",
      "value": 2753325,
      "recentSlope": -283287.5,
      "previousSlope": 158640
    },
    "rsi": 53.24,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 337.6857,
      "position": "SAR喺價上",
      "distancePct": 3.95,
      "previousTrend": "下降"
    },
    "ma50": 307.5992,
    "macd": {
      "macd": 6.009575844539029,
      "trend": "中性偏多",
      "signal": 8.494838295879006,
      "histogram": -2.4852624513399775
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 330.1014,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "有量",
      "ratio": 1.04,
      "score": 6,
      "avgVolume": 585844,
      "currentVolume": 610675
    },
    "derived": {
      "ma20": 329.565,
      "ma50": 307.5992,
      "prevClose": 326.89,
      "avgVolume10": 616508,
      "avgVolume20": 585844,
      "changePercent": -0.62,
      "avgVolumeForScore": 585844
    },
    "ma_cross": {
      "ma20": 329.565,
      "ma50": 307.5992,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 329.3875,
      "prevMa50": 306.5314,
      "spreadPct": 7.14,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 317.3381,
      "upper": 341.7919,
      "position": "中間"
    },
    "rsi_short": 22.07,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 1.04
    }
  }
}

Raw metrics JSON

{
  "close": 324.86,
  "volume": 610675,
  "changePercent": -0.62
}

Scores are derived from cached daily market data using the Cursor_18.25 standard. Solorank.ai provides research support only and does not provide financial advice or buy/sell recommendations.